SVA - シノバック・バイオテック (Sinovac Biotech Ltd.) シノバック・バイオテック

 SVAのチャート


 SVAの企業情報

symbol SVA
会社名 Sinovac Biotech Ltd (シノバック・バイオテック)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 医薬品   医療関連(Health Care)
概要 事業概要 シノバク・バイオテク(Sinovac Biotech Ltd.)は中国の統合型バイオ医薬品会社であり、伝染病予防のためのワクチンの研究、開発、製造及び商業化に注力する。同社はA型肝炎、B型肝炎及びインフルエンザ・ウイルス、H5N1とH1N1パンデミックインフルエンザや流行性耳下腺炎、並びに動物の狂犬病ワクチンに対応するワクチンにより構成される製品ポートフォリオを開発する。同社の製品パイプラインには、ロタウイルス、前臨床開発中である人間の狂犬病に対するヒトワクチンを含む。同社は特にアンメット?メディカル?ニーズを持つ感染症向けのワクチンを開発、生産と販売する。同社は中国において、肺炎球菌、ロタウイルス、狂犬病、水痘、風疹向けのEV71ワクチンとヒト用ワクチンの前臨床・臨床開発段階のワクチン候補により構成されるパイプラインを有する。   シノバック・バイオテックは、中国のバイオ医薬品会社。子会社を通じ、インフルエンザ、A 型肝炎、流行性耳下腺炎(おたふく風邪)、狂犬病などのワクチンに関する研究開発、生産、販売を手掛ける。中国をはじめ、モンゴル、ネパ―ル、フィリピン、メキシコなどで製品を販売。本社は北京。   Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases. Sinovac's product portfolio includes vaccines against enterovirus71 (EV71), hepatitis A and B, seasonal influenza, 23-Valent Pneumococcal Polysaccharide ('PPV'), H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), varicella vaccine and mumps. Healive, the hepatitis A vaccine manufactured by the Company, has passed the assessment under WHO prequalification procedures in 2017. The EV71 vaccine, an innovative vaccine developed by Sinovac against hand foot and mouth disease caused by EV71, was commercialized in China in 2016. In 2009, Sinovac was the first company worldwide to receive approval for its H1N1 influenza vaccine, which it has supplied to the Chinese Government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine to the government stockpiling program. The Company is developing a number of new products including COVID-19 vaccine, CoronaVac, a Sabin-strain inactivated polio vaccine and combined vaccines. Sinovac primarily sells its vaccines in China, while also exploring growth opportunities in international markets. The Company is seeking market authorization of its products in over 30 countries outside of China.
本社所在地 No. 39 Shangdi Xi Road Haidian District Beijing 100085 CHN
代表者氏名 WeiDong Yin WeiDong Yin
代表者役職名 Chairman of the Board President Chief Executive Officer Secretary
電話番号 +86 10-8289-0088
設立年月日 36220
市場名 NASDAQ National Market System
ipoyear ―年
従業員数 835人
url www.sinovac.com
nasdaq_url https://www.nasdaq.com/symbol/sva
adr_tso
EBITDA EBITDA(百万ドル) 50.21400
終値(lastsale) 7.6238
時価総額(marketcap) 526666291.8918
時価総額 時価総額(百万ドル) 447.87630
売上高 売上高(百万ドル) 174.34600
企業価値(EV) 企業価値(EV)(百万ドル) 366.46230
当期純利益 当期純利益(百万ドル) 25.80700
決算概要 決算概要 BRIEF: For the fiscal year ended 31 December 2017 Sinovac Biotech Ltd. revenues increased from $72.4M to $174.3M. Net income before extraordinary items totaled $25.8M vs. loss of $2.9M. Revenues reflect Enterovirus 71 vaccines segment increase from $35.1M to $121.3M Inactivated hepatitis vaccines segment increase of 84% to $37.9M Hong Kong segment increase of 16% to $1.4M.

 SVAのテクニカル分析


 SVAのニュース

   US Futures Fade Asian Rally On Fears ECB Will Take Away The Punchbowl  2021/09/07 11:53:04 Zero Hedge
US Futures Fade Asian Rally On Fears ECB Will Take Away The Punchbowl European bourses dipped in the red and a rally in US equity futures which traded near all-time highs after the Labor Day holiday fizzled, as investors weighed Chinas better-than-forecast trade data against the growing likelihood of fading central-bank support. S&P500 futures traded fractionally in the green and Nasdaq 100 indexes slipped and equity gains in China and Japan were followed by losses in Europe as investors speculated the ECB may get ready to roll back stimulus. The dollar and Treasuries yields rose, gold and cryptos dropped. Tech gigacaps such as Microsoft, Amazon.com and Facebook eased about 0.2% each, while Apple and Google were slightly higher. Tracking benchmark bond yields higher, banks including Wells Fargo, Goldman Sachs, Citigroup and JP Morgan rose between 0.4% and 0.5%. Among meme stocks, IronNet more than doubled in value in premarket trading after the cybersecurity company was touted on Reddit and StockTwits.
   Chinese-made vaccine suspended for operating unauthorized plant in Brazil  2021/09/07 07:56:42 BLDaily The BL
Brazils health regulator temporarily blocked more than 12 million doses of Sinovac Biotechs COVID-19 vaccine on Sept. 4. Anvisa took regulatory action after receiving a complaint from Sao Paulos Butantan Institute biomedical center. The center, which helps the Chinese firm manufacture locally, accused the Asian pharmaceutical company of unlawfully producing several vaccine batches in an []
   Chile approves Sinovac for use on children above six  2021/09/07 05:13:42 Report AZ
Chilean health authorities approved on Monday the use of the Sinovac vaccine against the coronavirus for 6-year-old children and older.
   Sinovac booster shot reverses drop in antibody activities against COVID-19 Delta variant, says study  2021/09/07 05:02:34 Express Pharma
Several countries which have relied heavily on the Sinovac vaccine have begun giving booster shots developed by Western manufacturers to people fully vaccinated with the Chinese shot The post Sinovac booster shot reverses drop in antibody activities against COVID-19 Delta variant, says study appeared first on Express Pharma .
   Chile approves emergency use of China''s vaccines for children aged 6-17  2021/09/07 03:18:03 Big News Network
SANTIAGO, Sept. 6 (Xinhua) -- Chile''s Institute of Public Health (ISP) on Monday approved the emergency use of Sinovac CoronaVac vaccines made by Chinese pharmaceutical firm Sinovac Biotech for children and adolescents aged from 6 to 17. ISP Director Heriberto Garcia made the announcement at a press conference held after a meeting of experts on the use of the drug. "In order to continue protecting the pop
   SINOVAC In Deal With Gavi To Supply 380 Mln Doses Of CoronaVac Through COVAX  2021/07/12 10:03:06 Business Insider Markets
(RTTNews) - Chinese biopharmaceutical company Sinovac Biotech Ltd. (SVA) announced Monday that it had signed an advance purchase agreement or APA with Gavi, the Vaccine Alliance, to supply up to 380 million doses of inactivated COVID-19 vaccine, CoronaVac, for distribution through the COVAX Facility. Under the deal, SINOVAC will supply 50
   SINOVAC Enters Into Agreement to Supply CoronaVac® to COVAX  2021/07/12 09:40:00 Business Wire
BEIJING--(BUSINESS WIRE)--SINOVAC Biotech Ltd. (NASDAQ: SVA) (Sinovac or the Company), a leading provider of biopharmaceutical products in China, announced today that it had signed an advance purchase agreement (APA) with Gavi, the Vaccine Alliance (Gavi), which is on behalf of COVAX Facility, to provide up to 380 million doses of inactivated COVID-19 vaccine, CoronaVac®for distribution through the COVAX Facility. According to the APA, SINOVAC will supply 50 million doses of CoronaVac® by t
   Deaths in Indonesia from COVID-19 raises sharply, numbers doubled in 2 days  2021/07/08 22:55:08 Sify.com
Jakarta [Indonesia], July 9 (ANI): Indonesia, the world''s fourth most populous nation is grappling with COVID-19 deaths, and the numbers have doubled in two days since Wednesday. As per Wall Street Journal (WSJ), the fast-spreading Delta variant of the coronavirus has overwhelmed the largely unvaccinated country''s healthcare system. Around 5 per cent of Indonesia''s 270 million people are fully vaccinated and infections have been rising for days. The country reported a record 1,040 deaths from Covid-19 on Wednesday, up from 558 deaths two days ago, reported WSJ. Hospitals in many parts of the archipelago have run out of beds and ventilators. Fears of oxygen scarcity have led authorities to import supplies from abroad. Hundreds of healthcare workers who were fully inoculated with shots developed by China''s Sinovac Biotech Ltd - which make up the bulk of Indonesia''s current vaccine supply - are infected with COVID-19, reducing the medical manpower available to deal with the flow of patients, doctors'' associations said, reported WSJ. "Now we are in a very severe situation," said Dicky Budiman, an Indonesian epidemiologist at Griffith University in Australia, adding that cases were likely to rise further in the coming days.
   Fallece la científica encargada de las pruebas de la vacuna Sinovac  2021/07/08 18:15:36 El Dictamen
Novilia Sjafri Bachtiar, la científica de Indonesia encargada del equipo que realiza las pruebas clínicas de la vacuna china Sinovac en Indonesia, falleció este miércoles por razones no aclaradas, aunque algunos medios indican que probablemente se debió al Covid-19. La doctora falleció el 7 de julio, día que registró por primera vez más de mil muertos en la peor […] Esta noticia Fallece la científica encargada de las pruebas de la vacuna Sinovac puedes leerla completa en El Dictamen .
   Arriban al AICM lote con un millón de vacunas contra Covid-19 de SinoVac  2021/07/08 17:49:29 Uno mas Uno
Un nuevo lote con un millón de dosis de la vacuna contra el coronavirus, desarrollada por la farmacéutica SinoVac, llegó hoy al Aeropuerto Internacional de […]
   La vacuna china de Sinovac se considera altamente efectiva en el mundo real: protege de la hospitalización con un 96% de eficacia a los 7 días  2021/05/12 07:19:12 Business Insider Spain
El seguimiento de más de 23.000 trabajadores de la Salud en Indonesia ha evidenciado que la vacuna es un 96% y 100% eficaz para reducir hospitalizaciones y muertes.
   Los datos de las vacunas chinas de Sinopharm y Sinovac muestran eficacia, según la OMS  2021/03/31 11:08:29 Investing.com Spain
https://es.investing.com/news/stock-market-news/los-datos-de-las-vacunas-chinas-de-sinopharm-y-sinovac-muestran-eficacia-segun-la-oms-2099772
   Китайська вакцина проти COVID-19 надійде в Україну 25 березня, - "Лекхім"  2021/03/23 18:31:31 Censor.NET
Компанія-постачальник "Лекхім" заявила, що планує поставки вакцини CoronaVac китайської фармкомпанії Sinovac Biotech 25 березня.
   Китайската ваксина на "Синовак" е безопасна и ефикасна при деца и юноши  2021/03/23 17:21:00 Агенция КРОСС (Agencia KROSS)
/КРОСС/ Китайската ваксина на "Синовак" е безопасна и ефикасна при деца и юноши на възраст между 3 и 17 години, предадоха Асошиейтед прес и Ройтерс, позовавайки се на компанията. Резултатите са от изпитвания в начална и междинна фаза, обхванали над 500 изследвани лица, съобщи на пресконференция Гън Дзън, медицински директор на "Синовак". Въпреки че ваксината вече е разрешена за употреба при възрастни в Китай, бяха необходими допълнителни тестове, за да се види как ще действа при деца. Над 70 милиона инжекции на ваксината на "Синовак" са направени по целия свят, включително в Китай. В изпитванията са наблюдавани два случая на висока температура в отговор на ваксината - при деца на 3 и 6 години. Останалите участници са проявили леки симптоми, казва Гън. Държавната компания "Синофарм" - разработчик на две ваксини срещу COVID-19, също проучва ефективността им при деца.
   «Лекхім» планує першу поставку вакцин Sinovac 25 березня  2021/03/23 16:14:53 Ukrinform
Група компаній «Лекхім» планує здійснити поставку першої партії вакцин проти коронавірусу китайської компанії Sinovac Biotech 25 березня.

 関連キーワード  (医薬品 米国株 シノバック・バイオテック SVA Sinovac Biotech Ltd.)

 twitter  (公式ツイッターやCEOツイッターなど)